ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried and failed to expand its label since. This month an FDA AdComm voted against an approval in Alzheimer's disease psychosis, despite the FDA issuing positive briefing notes.

FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet

Kellogg

NetApp

As markets figure out a direction over the course of this summer, economic headwinds may be holding back some gains.

3 Big Ideas From Citigroup With Up to 80% Upside

Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.

Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?

An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.

Why Acadia Pharmaceuticals Stock Is Crashing Today

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check.

Biotech Stock Plummets After FDA Snub

A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-.

Why Acadia Pharma Shares Are Plunging Today

Shares of Acadia Pharmaceuticals Inc. ACAD, +3.94% were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks.

Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote

An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.

FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP p

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis

Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m.

Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company's common stock. The U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee is meeting virtually today to review the resubmitted NUPLAZID (pimavanserin) supplemental New Drug Application for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. The Advisory Committee meeting is scheduled for 8:45 a.m.

Acadia Pharmaceuticals Stock Trading Halted Today

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00.

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.

Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?

Ahead of Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations.

Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?

Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.

Why Acadia Pharmaceuticals Spiked Today

Axsome Therapeutics

bluebird bio

Bristol-Myers

Moderna

Rhythm Pharmaceuticals

Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report?

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro to Present at 12th Annual LD Micro Invitational Investor Conference; Focuses on Progress with Clinical Trials & INDs for AL001 & AL002

Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.

Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

ATLANTA--(BUSINESS WIRE)---- $ACAD #ACImmune--Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - CEO Brendan Teehan - COO and Head, Commercial Mark Schneyer - CFO Serge Stankovic - President Conference Call Participants Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Gregory Renza - RBC Capital Markets Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord David Hoang - SMBC Rudy Li - SVB Securities Chris Howerton - Jefferies Vamil Divan - Mizuho Securities Alex Thompson - Stifel Jay Olson - Oppenheimer Esther Hong - Berenberg Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals First Quarter 2022 Financial Results Conference Call. My name is Crystal and I'll be your coordinator for today.

ACADIA Pharmaceuticals Inc. (ACAD) CEO Stephen Davis on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022. “NUPLAZID continued to deliver year over year growth in the first quarter of 2022,” said Steve Davis, Chief Executive Officer. “In the near term, we are focused on preparing for the upcoming Advisory Committee meeting in connection with our resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis. In addition, we have aligned with th

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022. “We appreciate

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer's Disease Psychosis Scheduled for June 17, 2022

News for ACADIA Pharma Stock (ACAD)